Moleculin Biotech News

Moleculin Biotech (MBRX.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -$2.02, previous value of -$4.13, and expected value of -$3.53.

Moleculin Biotech (MBRX.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -$2.02, previous value of -$4.13, and expected value of -$3.53.

Zhitong FinanceMay 11 05:20

Moleculin Biotech Q1 EPS $(2.02) Beats $(3.53) Estimate

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(2.02) per share which beat the analyst consensus estimate of $(3.53) by 42.78 percent. This is a 51.9 percent increase over losses of $(4

BenzingaMay 11 05:09

Moleculin Biotech | 10-Q: Quarterly report

Futu NewsMay 11 04:38 · Announcements

Moleculin Biotech Secures Patent for Liposomal Drug Innovation

TipRanksMay 9 20:43

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

Patent, once issued, will provide composition protection through 2040, with potential for additional term extensionAnnamycin is advancing towards pivotal AML study in 2024 and may qualify for an accel

Moleculin BiotechMay 9 12:00

Moleculin Biotech's Annamycin Shows Promising Efficacy in AML Treatment, Backed by Strong Clinical Results and Buy Rating

Maxim Group analyst Jason McCarthy maintained a Buy rating on Moleculin Biotech (MBRX – Research Report) yesterday and set a price target of $20.00.

TipRanksMay 9 02:35

Moleculin Biotech Announces Upcoming Quarterly Financial Results

TipRanksMay 8 20:42

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast

HOUSTON, May 8, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-trea

Moleculin BiotechMay 8 12:00

Moleculin Biotech Shares Corporate Update Online

TipRanksMay 8 04:23

Moleculin Biotech Shares Upbeat Annamycin AML Trial Update

TipRanksMay 7 21:13

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability With Additional Interim Subject Data

Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13) Full MB-106 trial reaches 20 subjects with CRc of 45% in 1st – 7th line, wi

Moleculin BiotechMay 7 12:00

Moleculin Biotech Hosts AML Clinical Insights Virtual Event

TipRanksMay 2 21:12

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the treatment of acute myeloid leukemia (AML), Annamycin and the Com

Moleculin BiotechMay 2 12:00

Press Release: Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin PR Newswire HOUSTON, May 1, 2024 -- Company appoints internationally renowned clinician, Martin S.

Dow JonesMay 1 20:50

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

– Company appoints internationally renowned clinician, Martin S. Tallman, MD as inaugural clinician memberHOUSTON, May 1, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company)

Moleculin BiotechMay 1 12:00

12 Health Care Stocks Moving In Friday's Pre-Market Session

GainersTevogen Bio Holdings (NASDAQ:TVGN) shares rose 75.3% to $1.49 during Friday's pre-market session. The company's market cap stands at $245.2 million. Cryo-Cell International (AMEX:CCEL) shares i

BenzingaApr 26 20:06

Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 / JTC Team , a fully

AccesswireApr 25 21:45

Moleculin Biotech Shares Corporate Direction Insights

TipRanksApr 25 20:32

Sector Update: Health Care Stocks Ease in Afternoon Trading

Health care stocks eased Thursday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both 0.1% lower. The iShares Biotechnology ETF (IBB) fell 0.7%. In corpora

MT NewswiresApr 19 01:56

Moleculin Biotech's Annamycin Granted Orphan Drug Status in EU

TipRanksApr 18 20:43